Vessel Deformations and Restenosis After Stenting of the Popliteal Artery (FIRESTEP)
Primary Purpose
Peripheral Arterial Disease, Popliteal Artery Stenosis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Interwoven stent
Laser-cut stent
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- Written informed consent prior to any study procedure,
- Presence of PAD (2 - 3 Rutherford-Becker class),
- Atherosclerotic de-novo lesion (stenosis >70% or occlusion) of the distal part of the superficial femoral artery and/or any part of the popliteal artery,
- Target lesion-length: 4cm to 12cm,
- Target vessel diameter: 5mm to 7mm,
- Guidewire must cross target lesion and located intraluminally before randomization,
- At least one (1) patent below-the knee artery (=with no stenosis >50%),
- Possibility to treat the target lesion with one (1) study stent
- Interventions in TASC A and B lesions to restore adequate blood flow, in the same index procedure, are allowed. This intervention must be prior to the treatment of the study lesion(s) and successful.
Exclusion Criteria:
- Pregnancy,
- Angiographic evidence of thrombus within the target lesion,
- Patients with acute critical limb ischemia (Rutherford-Becker class 4-6),
- Restenosis of the target lesion,
- Non-atherosclerotic obstructions of the target lesion,
- Aneurysm of the target lesion,
- Renal failure, defined as GFR, <40 mL/min/1.73m2,
- Patient's inability to follow the study procedures e.g. psychological disorders, dementia, etc.,
- Previous enrolment into an ongoing study,
- Known or suspected allergies or contraindications to aspirin and/or clopidogrel, heparin,
- Coagulation disorders, or general refusal of the patient to receive blood transfusions,
- Contrast allergy that cannot be treated,
- Thrombolysis therapy including 72 hours before the planned index procedure,
- Myocardial infarction or stroke <30 days prior to index procedure.
- Equipment is unavailable to fulfill study treatments.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Interwoven stent
Laser-cut stent
Arm Description
Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Outcomes
Primary Outcome Measures
Primary patency
Primary patency of the target lesion measured by duplex ultrasound
Secondary Outcome Measures
Changes in arterial flow within the target lesion
Changes in blood flow/hemodynamics caused by the different stent designs measured by Computational Fluid Dynamics
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04700371
Brief Title
Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
Acronym
FIRESTEP
Official Title
Flexion-Induced Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 1, 2023 (Anticipated)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kantonsspital Aarau
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The femoro-popliteal (FP) artery is the most frequently treated vascular segment in patients with symptomatic peripheral artery disease (PAD), for which endovascular therapy became an established treatment option during the last decades. However, loss of primary patency and consecutive clinically driven target lesion revascularization (TLR) limit this procedure. Moreover, in the popliteal artery (PA), evidence about the best treatment strategy to prevent loss of patency and TLR is limited to only a few randomized controlled trials (RCT). Arterial deformations of the PA with its unique anatomical properties during leg flexion might explain the poor technical and clinical outcomes in this segment. Generally, a "leave nothing behind" strategy in the PA is preferred, but cannot be avoided in all cases due to e.g. flow limiting dissections or re-coil after balloon angioplasty. Basically two different self-expandable nitinol-based stent designs are available on the market. An interwoven nitinol and laser-cut nitinol stent. The interwoven nitinol stent has a higher radial force in comparison to the laser-cut stent and reveals higher patency rates in the FP arteries. However, a head-to-head comparison of these stents is missing and it remains unknown in which way different stent designs affect the deformation and hemodynamic behaviors of the PA during knee flexion.
Detailed Description
Randomized trial to investigate the impact of different stent designs on the target lesion restenosis rate in femoro-popliteal arteries. Immediately after stent implantation, sets of three orthogonal angiographic views (separated by an angle of > 25°) of the stented region (TL) will be obtained with the leg in supine position. This will be followed by intra-arterial imaging using Optical Coherence Tomography (OCT). OCT images (one pullback if the lesion length is < 75 mm, 2 pullbacks otherwise) of the TL will be acquired using the Dragonfly catheter. In addition, duplex ultrasound (DU) of the TL will be performed, including the arterial segments 10cm at proximal and distal edge of the TL. Thereafter, a bending cast will be used to obtain a knee/hip flexion of approximately 70°/20°. In this position the angiographic, OCT, and DU measurements will be repeated.
The OCT images will provide the shapes of the arterial lumen which will be used to generate 3D surface models (in .stl format). The X-ray images will be utilized to construct the 3D arterial centerline for the supine and flexed leg positions. These arterial centerlines will be used to quantify the axial deformation (in mm), twisting (in °), and curvature changes (in mm-1) along the length of the investigated segment. Additionally, the lumen profiles obtained from OCT images will be used to accurately estimate the radial deformations (in mm) in the lumen and define instances of arterial pinching during leg flexion (as the difference in lumen diameters between straight and flexed leg positions).
The geometries of the arterial lumens will be combined with their corresponding 3D arterial centerlines to generate patient-specific arterial models. Along with patient-specific boundary conditions obtained from DU measurements, these models will be transferred to a commercial software, to perform Computational Fluid Dynamics analyses. The changes in these parameters due to leg flexion, as well as due to different stent designs, will be quantified.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Popliteal Artery Stenosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Interwoven stent
Arm Type
Active Comparator
Arm Description
Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Arm Title
Laser-cut stent
Arm Type
Active Comparator
Arm Description
Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Intervention Type
Device
Intervention Name(s)
Interwoven stent
Intervention Description
Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Intervention Type
Device
Intervention Name(s)
Laser-cut stent
Intervention Description
Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Primary Outcome Measure Information:
Title
Primary patency
Description
Primary patency of the target lesion measured by duplex ultrasound
Time Frame
1 year post index procedure
Secondary Outcome Measure Information:
Title
Changes in arterial flow within the target lesion
Description
Changes in blood flow/hemodynamics caused by the different stent designs measured by Computational Fluid Dynamics
Time Frame
6 weeks, 6 months, and 1 year post index procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent prior to any study procedure,
Presence of PAD (2 - 3 Rutherford-Becker class),
Atherosclerotic de-novo lesion (stenosis >70% or occlusion) of the distal part of the superficial femoral artery and/or any part of the popliteal artery,
Target lesion-length: 4cm to 12cm,
Target vessel diameter: 5mm to 7mm,
Guidewire must cross target lesion and located intraluminally before randomization,
At least one (1) patent below-the knee artery (=with no stenosis >50%),
Possibility to treat the target lesion with one (1) study stent
Interventions in TASC A and B lesions to restore adequate blood flow, in the same index procedure, are allowed. This intervention must be prior to the treatment of the study lesion(s) and successful.
Exclusion Criteria:
Pregnancy,
Angiographic evidence of thrombus within the target lesion,
Patients with acute critical limb ischemia (Rutherford-Becker class 4-6),
Restenosis of the target lesion,
Non-atherosclerotic obstructions of the target lesion,
Aneurysm of the target lesion,
Renal failure, defined as GFR, <40 mL/min/1.73m2,
Patient's inability to follow the study procedures e.g. psychological disorders, dementia, etc.,
Previous enrolment into an ongoing study,
Known or suspected allergies or contraindications to aspirin and/or clopidogrel, heparin,
Coagulation disorders, or general refusal of the patient to receive blood transfusions,
Contrast allergy that cannot be treated,
Thrombolysis therapy including 72 hours before the planned index procedure,
Myocardial infarction or stroke <30 days prior to index procedure.
Equipment is unavailable to fulfill study treatments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aljoscha Rastan
Phone
0041628386458
Email
aljoscha.rastan@ksa.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Christoph Thalhammer
Phone
0041628384703
Email
christoph.thalhammer@ksa.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aljoscha Rastan
Organizational Affiliation
Kantonsspital Aarau
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
We'll reach out to this number within 24 hrs